AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01533922 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT01533922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study NCT01067222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 oral capsules at 10 or 20 or 40 mg per day
Study NCT01067222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil oral capsules at 100 or 200 or 400 mg per day
Study NCT01067222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules, 4 capsules per day
Study NCT00101907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
Study NCT03328858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic Diet
Description: Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
Study NCT00101907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
Study NCT00675896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Sustained Release
Description: 50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
Study NCT00675896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
Study NCT03968783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monofilament suture
Description: 1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
Study NCT03968783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifilament suture
Description: 1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
Study NCT03412604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
Study NCT02662179 — intervention group
Intervention type: OTHER
Intervention: Quality of life evaluation
Description: Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
Study NCT02662179 — intervention group
Intervention type: OTHER
Intervention: Functional decline assessment
Description: Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
Study NCT02662179 — intervention group
Intervention type: OTHER
Intervention: Physical decline assessment
Description: Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
Study NCT01184027 — intervention group
Intervention type: BEHAVIORAL
Intervention: nutrition /swallowing intervention
Description: Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
Study NCT02893800 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Locating system watch with GPS-technology
Description: Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
Study NCT02662179 — intervention group
Intervention type: OTHER
Intervention: Cognitive decline assessment
Description: Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
Study NCT02634606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Delta Tocotrienols - Low Dose
Description: 250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
Study NCT03030651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education and Support
Description: Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
Study NCT03091569 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
Study NCT03783221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
Study NCT03783221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-residue diet
Description: The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
Study NCT02634606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Delta Tocotrienols - High Dose
Description: 250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
Study NCT02634606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
Study NCT01415206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Staging Health Risk Intervention (S-HRI)
Description: The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
Study NCT01415206 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
Study NCT02038049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: Single intravenous infusion of VAY736 (10 mg/kg)
Study NCT02038049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to VAY736
Study NCT03540329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Osteogenesis distractor
Description: Internal distraction osteogenesis in mandible
Study NCT03540329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Osteogenesis distractor
Description: External distraction osteogenesis in mandible
Study NCT00329914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Vaginal pessaries, 200 mg/day
Study NCT00329914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pessaries containing peanut oil
Study NCT03377049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 1 g acetazolamide through a peripheral IV line
Study NCT02068157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02068157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo image-guided I-PDT
Study NCT02068157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV
Study NCT02191839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha 1-Antitrypsin
Study NCT01890278 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain IMRT
Study NCT01890278 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Whole Brain RT
Study NCT02002689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
Study NCT02679820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T intrauterine device
Study NCT02482402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost
Description: Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
Study NCT02482402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhalation solution placebo
Study NCT04221191 — intervention group
Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: DMF as prescribed as standard of care.
Study NCT04221191 — intervention group
Intervention type: OTHER
Intervention: PSP
Description: PSPs is to support patient care.
Study NCT01496105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT01496105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT01013363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPod Nano digital music player
Description: Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
Study NCT00202033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: frequency of self monitoring blood glucose
Description: Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
Study NCT03546218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application (SPSRS)
Description: Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli.
Study NCT03546218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone Application (YouTube)
Description: Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
Study NCT02395211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy
Description: Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks
Study NCT02395211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gloreha device
Description: Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
Study NCT02801890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection
Description: Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
Study NCT02801890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous injection
Description: Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
Study NCT04637919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN-B001 EV71 A dose
Description: Inactivated vaccine against EV71, three doses, 28 days interval
Study NCT04637919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN-B001 CVA16 B dose
Description: Inactivated vaccine against CVA16, three doses, 28 days interval
Study NCT04637919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN-B001 Bivalent C dose
Description: Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
Study NCT04637919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval
Study NCT04049929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
Study NCT02759315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir 450 mg
Description: 450 mg administered as 3 x 150 mg oral tablets
Study NCT00101907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
Study NCT01333865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated.
Study NCT03345875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment
Description: Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
Study NCT04094662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Description: Mirogabalin tablets for oral administration
Study NCT04094662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral administration
Study NCT00953784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard operating management
Description: As previously described
Study NCT01491711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylaminolevulinate PDT in 2 sessions
Description: The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
Study NCT01491711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
Description: The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
Study NCT01926366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6423
Description: Drug: AZD6423 Single or Multiple doses via infusion.
Study NCT01926366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
Study NCT03302923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking
Description: Prospective randomized clinical trial with 2 intervention groups and 1 control group.
Study NCT00591786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
Study NCT00101907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
Study NCT00851435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KBPA-101
Description: 1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
Study NCT03485820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS
Description: The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
Study NCT02593643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02593643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02593643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
Study NCT02593643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
Study NCT02759315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg
Description: 60 mg administered as 6 x 10 mg oral capsules